Publications by authors named "Kadiane-Oussou N"
Objective: The aim of this study was to determine the prevalence of HBsAg carriage in candidates for gendarmerie recruitment.
Methods: This was a prospective cross-sectional study conducted from April 7, 2010 to September 12, 2010 at the Abidjan military hospital. It involved candidates for the national gendarmerie competitive examination who agreed to take part in the study.
Long-term evolution data of olfactory disorders (OD) in COVID-19 are limited. ANOSVID is a retrospective study in Nord Franche-Comté Hospital (France) that included COVID-19 patients from the first wave. The aim was to describe OD evolution, especially in patients with persistent OD (p-OD group) in comparison with patients with resolved OD (r-OD group).
View Article and Find Full Text PDFOlfactory disorders (OD) pathogenesis, underlying conditions, and prognostic in coronavirus disease 2019 (COVID-19) remain partially described. ANOSVID is a retrospective study in Nord Franche-Comté Hospital (France) that included COVID-19 patients from March 1 2020 to May 31 2020. The aim was to compare COVID-19 patients with OD (OD group) and patients without OD (no-OD group).
View Article and Find Full Text PDFArticle Synopsis
- Tocilizumab trials show mixed results partly due to the diverse patient populations involved.
- A meta-analysis included nine studies, revealing a lower mortality rate in the tocilizumab group (24.5%) compared to the control group (29.1%), particularly for severe COVID-19 patients.
- The study concludes that tocilizumab effectively improves survival and reduces the need for mechanical ventilation in hospitalized COVID-19 patients, especially those with severe cases.
In this article, we express our opinion about tocilizumab as an effective treatment in coronavirus disease 2019, based on a narrative review and a deep analysis of tocilizumab randomised trial results. Eight trials were included. No one was in favour for controlled arm about main endpoint of death or mechanical ventilation incidence at day 28-30.
View Article and Find Full Text PDFIn this article, we sought to summarize the available evidence of tocilizumab as a treatment for coronavirus disease 2019. Recent tocilizumab randomized trials have not shown clear evidence of efficacy, especially on mortality, in contrast to observational studies. These clinical trials focus on a heterogeneous population of patients (clinical severity and inflammatory stage), and this is possibly one of the reasons that explain heterogeneity of results.
View Article and Find Full Text PDFThe main localization of SARS-CoV-2 infection is the respiratory tract. Digestive and otorhinolaryngological localizations are also reported. More recently, dermatological manifestations have been reported during Coronavirus disease-19 (COVID-19).
View Article and Find Full Text PDFCOVID-19 patients (n = 114) were included (55 patients with pneumonia (group P) and 59 without pneumonia (group NP). Patients in group P were older (69 (±17) years vs 46 (±16); p < 0.001) with a male predominance (58.
View Article and Find Full Text PDFIntroduction: No therapy has proven to be effective yet to reduce mortality and/or invasive mechanical ventilation (IMV) requirement in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment.
Methods: We conducted a retrospective case-control study in the Nord Franche-Comté Hospital, France.
Background: New loss of smell or taste was not included as common symptoms of COVID-19 until March 2020 when the pandemic started in Western countries. We want to describe the prevalence and features of anosmia and dysgeusia in COVID-19 patients.
Methods: We retrospectively investigated the clinical features of confirmed cases of COVID-19 in Nord Franche-Comté Hospital, Trevenans, France, between March, 1st and March, 14th 2020.
Objectives: Acute respiratory distress syndrome (ARDS) related to SARS-CoV-2 is likely due to a cytokine storm characterised by a major release of pro-inflammatory cytokines, including interleukin-6 (IL-6). Blocking excessive IL-6 production might be the key to the COVID-19-ARDS treatment. Beneficial effects of IL-6 blockade using a humanised anti-IL-6 receptor antibody, tocilizumab (TCZ) were previously reported in patients with COVID-19 related ARDS.
View Article and Find Full Text PDFClinical descriptions about influenza-like illnesses (ILI) in COVID-19 seem non-specific. We aimed to compare the clinical features of COVID-19 and influenza. We retrospectively investigated the clinical features and outcomes of confirmed cases of COVID-19 and influenza in Nord Franche-Comté Hospital between February 26th and March 14th 2020.
View Article and Find Full Text PDFIntroduction: No therapy has yet proven effective in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment.
Method: We conducted a retrospective case-control study in the Nord Franche-Comté Hospital, France.
Diarrhea: An underestimated symptom in Coronavirus disease 2019.
Clin Res Hepatol Gastroenterol
June 2020
In a retrospective study in the Nord Franche-Comté hospital conducted between March 1st and March 17th 2020, and compared to the review of Li et al., diarrhea was a main symptom in patients with COVID-19. Out of the 114 patients, 55 (48%) had diarrhea; it was the fifth most common symptom.
View Article and Find Full Text PDFBackground: Medical publications about anosmia with COVID-19 are scarce. We aimed to describe the prevalence and features of anosmia in COVID-19 patients.
Methods: We retrospectively included COVID-19 patients with anosmia between March 1st and March 17th, 2020.